Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)NCT05371613 | DNLI | Phase 2, Phase 3 | Active not recruiting | 2027-12Estimated |
| An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007NCT06075537 | DNLI | Phase 2, Phase 3 | Enrolling by invitation | 2027-06Estimated |
| Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)NCT06602193 | DNLI | Phase 2 | Active not recruiting | 2027-03Estimated |
NCT05371613 · Denali Therapeutics Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Measure: Percent change from baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A)
Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A)
Measure: Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A)
Estimated
Actual
63 participants (planned)
65 participants (actual)
Recruiting
Active not recruiting
NCT06602193 · Denali Therapeutics Inc.
30 Apr 2026
Mar 2027
Recruiting
Active not recruiting
Trial